Biotech Values

[ghmm]

Good to see there is at least one more ITMN long here :)

Dew already caught me on one mistake but I am pretty sure I didn't write 191 is complete [in phase 1 studies]. If I gave that impress, certainly didn't mean to!! The notes are written more for myself and so something may have been abbreviated. To clarify things:

191 in Phase 1 studies as we speak, proof of concept data in 2007,

Enrollment "is" complete? That didn't didn't take long.
It is still in Phase 1. The way Tom Kassberg talked about it the Phase 1A and B trials are combined (that is my impression he didn't come out and say so). The proof of concept would be the 1B results.

Was the 175 million shelf filed recently?
The shelf was filed in late December. There is a separate 170 million convertible already on the books (conversion price of 21.63 which gives about 8 million shares combined with the 33 gives the fully diluted number)

I have a couple theories on this shelf. If I am right in my interpretation of the 170 million if holders elect to redeem early the company can pay in cash so they'd need the cash to do so. The other theories revolve around what the company may be planning with extra cash.


What we said is there are 2 interim looks (for efficacy). Very specific about not saying when/if they occurred just saying they have very specific efficacy stopping boundaries.

Is this in reference to the HCV study? I thought ITMN was testing healthy patients in Phase I? Has that changed?
2 Interim looks are for Actimmune (the INSPIRE trial).